Velocity Clinical Research

Velocity Clinical Research is a leading, rapidly expanding integrated clinical site organization that is actively setting a new global standard for how clinical trials are conducted at the actual patient and clinic level. Unlike traditional CROs that manage studies from a corporate distance, Velocity owns, operates, and fully integrates a massive, unified network of dedicated clinical research sites across North America and Europe. This wholly-owned, multi-site model allows Velocity to exert absolute, centralized control over the quality, speed, and consistency of trial execution.

Velocity specializes in high-volume, rapid-enrollment studies, a capability that proved critically important during recent global health crises; they played a highly pivotal and public role in the rapid enrollment and execution of multiple major COVID-19 vaccine trials for top pharma companies. Their deep therapeutic expertise extends broadly across vaccines, internal medicine, neurology, and dermatology.

By centralizing burdensome administrative, regulatory, and patient recruitment marketing functions at the corporate level, Velocity allows its principal investigators and site-level medical staff to focus entirely on direct patient care and highly accurate clinical data collection.

This unique organizational structure elegantly solves the chronic industry problem of site fragmentation and delayed enrollment, making Velocity an incredibly highly sought-after strategic partner for biopharmaceutical companies looking for reliable, high-speed, and high-quality clinical trial execution.